DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

Information source: Wuhan University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atrial Fibrillation

Intervention: catheter ablation (Procedure); Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Wuhan University

Official(s) and/or principal investigator(s):
Cong xin Huang, doctor, Study Chair, Affiliation: Renmin Hospital of Wuhan University

Overall contact:
Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn

Summary

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

Clinical Details

Official title: Atrial Fibrillation Therapy: A Multi-Center Clinical Study

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of participants with all-cause death

Number of participants with all-cause death

Number of participants with all-cause death

Number of participants with all-cause death

severe blooding complications

severe blooding complications

severe blooding complications

severe blooding complications

cardio-cerebrovascular complications

cardio-cerebrovascular complications

cardio-cerebrovascular complications

cardio-cerebrovascular complications

Number of participants with cardiovascular death events

Number of participants with cardiovascular death events

Number of participants with cardiovascular death events

Number of participants with cardiovascular death events

Secondary outcome:

recurrence of atrial arrhythmias (AF, AFL, AT)

recurrence of atrial arrhythmias (AF, AFL, AT)

recurrence of atrial arrhythmias (AF, AFL, AT)

recurrence of atrial arrhythmias (AF, AFL, AT)

resource utilization and costs

resource utilization and costs

resource utilization and costs

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age: 18-75 years 3 Patients

who are willing to enroll in the trial Exclusion Criteria:

- 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal

dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman

Locations and Contacts

Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn

Renmin Hospital of Wuhan University, Wuhan, Hubei, China; Recruiting
Cong xin Huang, doctor, Phone: 13907131546, Email: huangcongxin@yahoo.com.cn
cong xin Huang, doctor, Principal Investigator
Additional Information

Starting date: April 2011
Last updated: April 21, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017